With $55 series D, Seer plans to bring unbiased proteomics to the market

Seer raised $55 million in an oversubscribed series D round led by Israeli investor aMoon Fund -- a financial move the company thinks will make unbiased, high-throughput proteomics a commercial reality.

T. Rowe Price funds and other undisclosed new investors

Read the full 406 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers